G007-LK Tankyrase 1/2 Inhibitor: Precision Tool for Wnt/β-Catenin Signaling Research

Executive Summary: G007-LK is a highly selective small-molecule inhibitor of tankyrase 1 (TNKS1) and tankyrase 2 (TNKS2), with IC₅₀ values of 46 nM and 25 nM, respectively, under standardized enzymatic assay conditions (APExBIO). It blocks auto-poly(ADP-ribosyl)ation of TNKS1/2, leading to suppression of Wnt/β-catenin signaling and stabilization of AXIN1/2 proteins in both cell-based and in vivo models (Jia et al., 2017). In APC-mutant colorectal cancer and hepatocellular carcinoma models, G007-LK demonstrates robust antitumor efficacy and reduces cytosolic and nuclear β-catenin levels. The compound's solubility profile (≥26.5 mg/mL in DMSO, insoluble in water/ethanol) and recommended storage at -20°C facilitate reliable integration into cell biology workflows. Extensive peer-reviewed and product data support its role as a benchmark tankyrase inhibitor for mechanistic studies in cancer biology, cell cycle modulation, and pathway cross-talk (see review).

Biological Rationale

Tankyrases (TNKS1/2) are poly(ADP-ribosyl) polymerases (PARPs) involved in the regulation of Wnt/β-catenin signaling, telomere maintenance, glucose metabolism, and cell cycle progression (Jia et al., 2017). Dysregulation of tankyrase activity is implicated in multiple human cancers, including colorectal and hepatocellular carcinoma, due to aberrant stabilization of β-catenin and downstream transcriptional programs. In APC-mutant colorectal cancer, tankyrase inhibition leads to β-catenin degradation via stabilization of AXIN1/2, which are negative regulators of the pathway. Tankyrases also modulate the Hippo pathway by controlling the stability of angiomotin-like proteins (AMOTL1/2), which in turn regulate YAP/TAZ, key effectors in cell proliferation and organ size control. Therefore, selective inhibition of TNKS1/2 is a rational strategy for dissecting canonical and noncanonical signaling pathways relevant to oncogenesis and regenerative biology (G007-LK: Transforming Wnt/β-Catenin and Hippo Pathway Inh..., which this article extends by providing detailed quantitative benchmarks and workflow guidance).

Mechanism of Action of G007-LK tankyrase 1/2 inhibitor

G007-LK is a small-molecule inhibitor that binds to the catalytic PARP domain of both TNKS1 and TNKS2, preventing their auto-poly(ADP-ribosyl)ation activity (APExBIO). This inhibits the PARylation-dependent ubiquitination and subsequent degradation of AXIN1/2, leading to their accumulation. AXIN1/2 serve as scaffold proteins for the β-catenin destruction complex, which targets β-catenin for phosphorylation, ubiquitination, and proteasomal degradation. In Wnt-stimulated or APC-mutant cells, G007-LK treatment results in the formation of dynamic degradasomes containing phosphorylated β-catenin, β-TrCP, and ubiquitin, culminating in a rapid reduction of cytosolic and nuclear β-catenin levels. Additionally, tankyrase inhibition with G007-LK stabilizes AMOTL1/2 proteins, thereby suppressing YAP/TEAD-driven transcriptional activity in the Hippo pathway (Jia et al., 2017).

Evidence & Benchmarks

• G007-LK inhibits TNKS1 and TNKS2 auto-poly(ADP-ribosyl)ation with IC₅₀ values of 46 nM and 25 nM, respectively, in cell-free enzyme assays (APExBIO).
• In Wnt3a-induced HEK 293 cells, G007-LK suppresses Wnt signaling reporter ST-Luc with an IC₅₀ of 0.05 μM under 6-hour exposure conditions (Precision Tankyrase 1/2 Inhibitor for Wnt/β-catenin...).
• In APC-mutant SW480 colorectal cancer cells, G007-LK induces formation of degradasomes and reduces cytosolic/nuclear β-catenin, detectable by immunofluorescence and Western blot after 8–24 hours (Jia et al., 2017).
• In COLO-320DM xenograft mouse models, G007-LK (20–40 mg/kg, intraperitoneally, daily) reduces tumor volume by over 50% versus vehicle controls within 2–3 weeks, with concomitant decreases in TNKS1/2 and β-catenin protein levels (Jia et al., 2017).
• G007-LK synergizes with MEK and AKT inhibitors to further suppress hepatocellular carcinoma cell proliferation, as shown in colony formation assays (Jia et al., 2017).
• G007-LK stabilizes AMOTL1 and AMOTL2, resulting in decreased YAP levels and YAP/TEAD reporter activity in HCC cell lines (Jia et al., 2017).
• Compound solubility is ≥26.5 mg/mL in DMSO at room temperature; it is insoluble in water or ethanol, enabling high-concentration stock solutions for cell-based assays (APExBIO).

This article updates and expands upon Reliable Pathway Modulation with G007-LK Tankyrase 1/2 In... by providing new in vivo efficacy benchmarks and clarifying optimal solubility/storage parameters.

Applications, Limits & Misconceptions

G007-LK is primarily used in the following research contexts:

• Dissecting Wnt/β-catenin pathway regulation in cell and animal models, especially those with APC or β-catenin mutations.
• Studying the cross-talk between Wnt and Hippo pathways via AMOT/YAP axis modulation.
• Evaluating tankyrase dependency in colorectal and hepatocellular carcinoma, including cell proliferation, colony formation, and tumorigenicity assays.
• Mechanistic analysis of poly(ADP-ribosyl)ation-dependent protein regulation.

Common Pitfalls or Misconceptions

• G007-LK is not effective in cell lines or tumors lacking functional tankyrase expression or with β-catenin mutations conferring proteasome resistance (Jia et al., 2017).
• It is not a pan-PARP inhibitor and does not block PARP1/2 activity at relevant concentrations (APExBIO).
• G007-LK should not be used in aqueous buffers; it is insoluble in water and ethanol and must be dissolved in DMSO or compatible organic solvents.
• Long-term stock solutions (>1 week) may degrade at room temperature; store solutions at -20°C and use within days for best reproducibility.
• Its in vivo efficacy is established in xenograft models, but clinical translation requires further toxicological and pharmacokinetic validation.

For a strategic discussion of translational opportunities, see Beyond β-Catenin: Strategic Mechanistic Insights for Tran..., which this article complements with concrete workflow and quantitative data.

Workflow Integration & Parameters

• Compound preparation: Dissolve G007-LK in DMSO to obtain ≥26.5 mg/mL stock; for cell culture, dilute to desired working concentrations (typically 0.01–10 μM) immediately before use (APExBIO).
• Storage: Solid compound and DMSO stocks should be stored at -20°C; avoid repeated freeze-thaw cycles.
• Assay compatibility: Effective in cell viability/proliferation, reporter gene, immunoblot, and xenograft tumor growth assays (see above benchmarks).
• Controls: Include vehicle (DMSO) and, where appropriate, unrelated PARP inhibitors to confirm selectivity.
• Readout: Monitor β-catenin, AXIN1/2, AMOTL1/2, and YAP levels by Western blot or immunofluorescence; use pathway-specific luciferase reporters for functional validation.

For protocol troubleshooting and scenario-driven guidance on cell-based assays, this article extends G007-LK Tankyrase 1/2 Inhibitor: Mechanistic Precision an... by emphasizing storage, solubility, and rapid integration into standardized workflows.

Conclusion & Outlook

G007-LK is a benchmark, well-characterized inhibitor for dissecting tankyrase-mediated Wnt/β-catenin and Hippo pathway regulation in APC-mutant colorectal and hepatocellular carcinoma research models. Its nanomolar potency, pathway selectivity, and robust in vitro and in vivo efficacy position it as a gold standard for mechanistic and translational research. While current data are limited to preclinical models, ongoing studies are expanding its utility in combinatorial oncology and regenerative medicine. For ordering and detailed technical specifications, refer to the APExBIO G007-LK tankyrase 1/2 inhibitor product page.